Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by SuperMoneyon May 05, 2019 11:09am
90 Views
Post# 29712183

RE:RE:RE:2nd cohort update

RE:RE:RE:2nd cohort updateJack and Bigbanktheory, thanks for your formation that are very useful. Could you please summarize your findings? Meanwhile, What is your speculation on the share price based on your findings? Thanks very much. Good luck to all shareholders!


Jack4000 wrote:
 wrote: Jack4000:  i was referring to this message, 

 

Right on.    Thanks.

 

MonkVestor wrote: I think we're gonna get some results from the 2nd cohort (150 mg of CBD) pretty soon...so with a good outcome expected the wind will start blowin' in the right direction (last update march 22nd..)


Might start but don't look for a big change till we get PH III approval.

 



.
 

bigbanktheory wrote: it might be a bit of a logical step to compare how other medical mj companies have done in the past to possibly give us a bit of insight as to what might happen with the next round of results, 

 

June 2018 GW Pharma gets approval for Epidiolex and sp goes from $139 to $160



They were in PH III as of May 2017

March 2016 looks like they were in PH 2b and the SP had just doubled to $141 from a positive 120 person trial.

So, without going into it deeper it looks like we would see a bumb but not a blowout.  

 

 

 

 



Bullboard Posts